RNS Number:1220Z
Schering AG
25 July 2002

Cancer imaging agent Flucis(R) approved in the EU

Berlin, July 25, 2002 - Schering AG's (FSE: SCH, NYSE: SHR) cancer imaging agent
Flucis(R) for PET(Positron Emission Tomography) imaging has been approved in the
EU. The launch of Flucis(R) is expected within the next months, reference member
state for the Mutual Recognition Procedure (MRP) was France.

"The launch of Flucis(R) in the EU for the expanding market segment of PET will
further strengthen our core competence in in-vivo imaging," said Michael Rook,
Head of Schering's Diagnostics& Radiopharmaceuticals business area. "With new
developments such as Flucis(R) we will extend our leading role in research and
marketing in the field of diagnostics and radiopharmaceuticals."

Flucis(R) can be used in a very broad spectrum of diagnostic processes such as
diagnosis, staging, monitoring and the detection of recurrences of several
oncologic indications including head and neck cancer, lung cancer and malignant
lymphomas. Further oncologic indications of Flucis(R) include the staging and
detection of recurrences from colorectal cancer and melanoma.

Flucis(R), (18F) fludeoxyglucose, accumulates in cells with a high metabolic
activity (e.g. cancer cells) by mimicking glucose. It is blocked in the cellular
metabolic process and therefore remains trapped in the tumor cells allowing the
monitoring with Positron Emission Tomography (PET).

Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Fertility Control&Hormone Therapy, Diagnostics&
Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for
disabling diseases in the fields of the central nervous system, oncology and
cardiovascular system. As a global player with innovative products Schering AG
aims for leading positions in specialized markets worldwide. With in-house R&D
and supported by an excellent global network of external partners, Schering AG
is securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve the
quality of life: making medicine work

This press release has been published by Corporate Communication of Schering AG,
Berlin, Germany.

Your contacts at Corporate Communication:

Business: Dr Friedrich von Heyl, Tel.: +49-30-468 152 96;friedrich.vonheyl@schering.de

Investor Relations: Peter Vogt, Tel.: +49-30-468 128 38; peter.vogt@schering.de

Pharma: Dr Claudia Schmitt, Tel.: +49-30-468 158 05, claudia.schmitt@schering.de

Find additional information at: www.schering.de/eng


Certain statements in this press release that are neither reported financial
results nor other historical information are forward-looking statements,
including but not limited to, statements that are predictions of or indicate
future events, trends, plans or objectives. Undue reliance should not be placed
on such statements because, by their nature, they are subject to known and
unknown risks and uncertainties and can be affected by other factors that could
cause actual results and Schering AG's plans and objectives to differ materially
from those expressed or implied in the forward-looking statements. Certain
factors that may cause such differences are discussed in our Form 20-F and Form
6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG
undertakes no obligation to update publicly or revise any of these
forward-looking statements, whether to reflect new information or future events
or circumstances or otherwise.



                      This information is provided by RNS
            The company news service from the London Stock Exchange